Drug Profile
Research programme: antibody therapeutics - Eutilex
Alternative Names: EU-102; EU900Latest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Eutilex
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for research development in Cancer in South Korea (Parenteral)